Skip to main content

Table 1 Demographics and Patient RCC Characteristics

From: Survival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results

Characteristics Patients
N = 21
Age, median years (range) 56.0 (22-68)
Sex, n (%)  
Male 16 (76)
Female 5 (24)
Race, n (%)  
Caucasian 19 (91)
Black 1 (5)
Asian 1 (5)
Time from diagnosis to 1 st sunitinib dose, mean weeks (SD) 10.8 (6.41)
ECOG performance status, n (%)  
0 15 (71)
1 6 (29)
MSKCC risk [ 23 ], n (%)  
Favorable (0 risk factors) 0
Intermediate (1-2 risk factors) 15 (71)
Poor (≥3 risk factors) 6 (29)
Heng risk [ 24 ], n (%)  
Favorable (0 risk factors) 0
Intermediate (1-2 risk factors) 11 (52)
Poor (≥3 risk factors) 10 (48)
Fuhrman nuclear grade, n (%)  
Grade 2 5 (24)
Grade 3 9 (43)
Grade 4 7 (33)
Tumor Size, n (%)  
TX 2 (10)
T1 3 (14)
T2 1 (5)
T3 13 (62)
T4 2 (10)
Regional Lymph Nodes Staging, n (%)  
NX 10 (48)
N0 6 (29)
N1 1 (5)
N2 4 (19)
Distant Metastasis Staging, n (%)  
M1 21 (100)
  1. ECOG = Eastern Cooperative Oncology Group MSKCC = Memorial Sloan Kettering Cancer Center; n = number of patients; SD = standard deviation.